Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MCF7 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 7493.091 | 0.9212 | 0.8544 | 1.0859 | |
| MCF7 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 7493.091 | 0.5187 | 0.0927 | 1.0859 | |
| MCF7 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 7493.091 | 0.0090 | -0.9739 | 1.0859 | |
| MCF7 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 7493.091 | 0.0026 | -0.9916 | 1.0859 | |
| MDA-MB-134-VI | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 7494.09 | 0.9372 | 0.8837 | 1.0823 | |
| MDA-MB-134-VI | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 7494.09 | 0.8707 | 0.7599 | 1.0823 | |
| MDA-MB-134-VI | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 7494.09 | 0.9377 | 0.8845 | 1.0823 | |
| MDA-MB-134-VI | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 7494.09 | 0.8913 | 0.7982 | 1.0823 | |
| MDA-MB-134-VI | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 7494.09 | 0.9300 | 0.8704 | 1.0823 | |
| MDA-MB-134-VI | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 7494.09 | 0.9057 | 0.8252 | 1.0823 | |
| MDA-MB-134-VI | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 7494.09 | 0.8204 | 0.6657 | 1.0823 | |
| MDA-MB-134-VI | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 7494.09 | 0.2144 | -0.5179 | 1.0823 | |
| MDA-MB-134-VI | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 7494.09 | 0.0078 | -0.9774 | 1.0823 | |
| MDA-MB-157 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 7496.092 | 0.9524 | 0.9035 | 0.9861 | |
| MDA-MB-157 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 7496.092 | 0.9893 | 0.9782 | 0.9861 | |
| MDA-MB-157 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 7496.092 | 0.9603 | 0.9195 | 0.9861 | |
| MDA-MB-157 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 7496.092 | 0.9498 | 0.8983 | 0.9861 | |
| MDA-MB-157 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 7496.092 | 0.9967 | 0.9934 | 0.9861 | |
| MDA-MB-157 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 7496.092 | 0.9213 | 0.8405 | 0.9861 | |
| MDA-MB-157 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 7496.092 | 0.6680 | 0.3283 | 0.9861 | |
| MDA-MB-157 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 7496.092 | 0.0134 | -0.9747 | 0.9861 | |
| MDA-MB-157 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 7496.092 | 0.0061 | -0.9886 | 0.9861 | |
| MDA-MB-157 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 7498.091 | 1.0310 | 1.0541 | 1.1445 | |
| MDA-MB-157 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 7498.091 | 1.0273 | 1.0477 | 1.1445 | |
| MDA-MB-157 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 7498.091 | 1.0438 | 1.0764 | 1.1445 |